Reduced Anxiety Level by Therapeutic Interventions and Cell-Mediated Immunity in Panic Disorder Patients
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective: This study examined the relationship between reduced anxiety level by therapeutic interventions and cell-mediated immunity (CMI) in patients with panic disorder. Methods: The subjects consisted of 42 patients with panic disorder and 42 normal gender- and age-matched controls. Among the patients, 21 were randomly assigned to a combined treatment of cognitive-behavioral therapy and the benzodiazepine antianxiety agent ethyl loflazepate (2 mg daily), and 21 were assigned to the antianxiety agent only. The treatment lasted for 6 weeks. Cell-mediated immune function was measured by the lymphocyte proliferative response to phytohemagglutinin (PHA) and interleukin-2 (IL-2) production. The anxiety level was assessed by the Hamilton Rating Scale for Anxiety and the anxiety subscale of the Symptom Checklist-90 Revised. Results: Prior to treatment, the panic disorder patients had significantly lower IL-2 production and blastogenic response to PHA than the normal controls. However, no significant differences in CMI were found between the pretreatment and posttreatment period in either the patient group receiving medication only or the combined treatment group, though after treatment, patients were significantly less anxious than before treatment in both intervention groups. The delta change (posttreatment value minus pretreatment value) in the self-reported anxiety level was significantly associated with the delta change in the blastogenic response in the combined treatment group. Conclusion: These findings suggest that panic disorder may be associated with decreased CMI, and the reduced level of self-reported anxiety in the patients who underwent combined therapeutic intervention is likely to increase the blastogenic response. Further studies are needed to evaluate the long-term effects of treatment on immune function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, IL-4 and IL-2 have also been found to be increased in PD (Hoge et al, 2009;Koh and Lee, 2004;Rapaport and Stein, 1994) or not different from controls in individuals with PD (Tukel et al, 2012).”
From Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond (2017) · cites this paper as Koh and Lee, 2004
In the citing paper
“| Interleukin-2 | Decreased in GAD | Koh and Lee (2004),Rapaport and Stein (1994), and Vieira et al (2010) |”
From Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond (2017) · cites this paper as Koh and Lee (2004)
In the citing paper
“| Interleukin-2 | Decreased in GAD | Koh and Lee (2004),Rapaport and Stein (1994), and Vieira et al (2010) |”
From Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond (2017) · cites this paper as Koh and Lee (2004)
In the citing paper
“No significant differences in cell-mediated immunity were found in panic disorder patients after 6 weeks of CBT or CBT plus benzodiazepines (Koh and Lee, 2004).”
From Inflammatory markers changes following acceptance-based behavioral psychotherapy in generalized anxiety disorder patients: Evidence from a randomized controlled trial (2024) · cites this paper as Koh and Lee, 2004
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale
Derogatis, L. R., Rickels, K., & Rock, A. F. (1976) · British Journal of Psychiatry · doi:10.1192/bjp.128.3.280 · Cited by 2,298 · cited 1×
“of the Symptom Checklist-90 Revised (SCL-90-R) anxiety subscale [”
VAN BALKOM, A. J. L. M., BAKKER, A., SPINHOVEN, P., BLAAUW, B. M. J. W., SMEENK, S., & RUESINK, B. (1997) · The Journal of Nervous & Mental Disease · doi:10.1097/00005053-199708000-00006 · Cited by 211
Central nervous system toxicity of interferon
Rohatiner, A. Z., Prior, P. F., Burton, A. C., Smith, A. T., Balkwill, F. R., & Lister, T. A. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.63 · Cited by 183
Heldt, E., Manfro, G. G., Kipper, L., Blaya, C., Maltz, S., Isolan, L., Hirakata, V. N., & Otto, M. W. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000067188 · Cited by 87
Kampman, M., Keijsers, G. P. J., Hoogduin, C. A. L., & Hendriks, G.-J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0904 · Cited by 87
Psychoimmunoendocrine Aspects of Panic Disorder
Brambilla, F., Bellodi, L., Ferna, G., Battaglia, M., Sciuto, G., Diaferia, G., Petraglia, F., Panerai, A., & Sacerdote, P. (1992) · Neuropsychobiology · doi:10.1159/000118890 · Cited by 78
Mefford, I. N., & Heyes, M. P. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90136-b · Cited by 77
Reduced Lymphocyte Proliferation and Interleukin-2 Production in Anxiety Disorders
Koh, K. B., & Lee, B. K. (1998) · Psychosomatic Medicine · doi:10.1097/00006842-199807000-00015 · Cited by 60
Self-citation
Cited by
Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond
Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J., & Jovanovic, T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.146 · Cited by 786
Anxiety disorders and comorbid medical illness
Roy-Byrne, P. P., Davidson, K. W., Kessler, R. C., Asmundson, G. J. G., Goodwin, R. D., Kubzansky, L., Lydiard, R. B., Massie, M. J., Katon, W., Laden, S. K., et al. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.12.006 · Cited by 668
A Meta-Analytic Review of Adult Cognitive-Behavioral Treatment Outcome Across the Anxiety Disorders
Norton, P. J., & Price, E. C. (2007) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000253843.70149.9a · Cited by 612
Bandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., Cinosi, E., Davies, S., Domschke, K., Fineberg, N., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1190867 · Cited by 347
“…corticotropin-releasing hormone; NE, norepinephrine; E, epinephrine; ACh, acetylcholine, TNF, tumour necrosis factor; IL1, interleukin-1; IL6, interleukin-6; þ, stimulation; , inhibition. before pharmacological treatment, but after treatment, no significant differences were seen (Koh & Lee 2004).”
BackgroundBroad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder
Hoge, E. A., Brandstetter, K., Moshier, S., Pollack, M. H., Wong, K. K., & Simon, N. M. (2009) · Depression and Anxiety · doi:10.1002/da.20564 · Cited by 343
Salim, S., Chugh, G., & Asghar, M. (2012) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/b978-0-12-398314-5.00001-5 · Cited by 310
Shields, G. S., Spahr, C. M., & Slavich, G. M. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0431 · Cited by 283
Renna, M. E., O'Toole, M. S., Spaeth, P. E., Lekander, M., & Mennin, D. S. (2018) · Depression and Anxiety · doi:10.1002/da.22790 · Cited by 220
Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders
Furtado, M., & Katzman, M. A. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.036 · Cited by 173
Enhanced Th17 phenotype in individuals with generalized anxiety disorder
Vieira, M. M. M., Ferreira, T. B., Pacheco, P. A. F., Barros, P. O., Almeida, C. R. M., Araújo-Lima, C. F., Silva-Filho, R. G., Hygino, J., Andrade, R. M., Linhares, U. C., et al. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.07.018 · Cited by 118
A neuroimmunological perspective on anxiety disorders
Hou, R., & Baldwin, D. S. (2012) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1259 · Cited by 107
Lopresti, A. L. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417701996 · Cited by 93
Kampman, M., Keijsers, G. P. J., Hoogduin, C. A. L., & Hendriks, G.-J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0904 · Cited by 87
Cytokine alterations in panic disorder: A systematic review
Quagliato, L. A., & Nardi, A. E. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.094 · Cited by 95
Treatment-resistant panic disorder: clinical significance, concept and management
Chen, M., & Tsai, S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.001 · Cited by 80
Lambert, R. A., Harvey, I. M., & Poland, F. M. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.026 · Cited by 55
Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview
Vismara, M., Girone, N., Cirnigliaro, G., Fasciana, F., Vanzetto, S., Ferrara, L., Priori, A., D’Addario, C., Viganò, C., & Dell’Osso, B. (2020) · Brain Sciences · doi:10.3390/brainsci10080564 · Cited by 46
Anxiety Disorders and Comorbid Medical Illness
Roy-Byrne, P. P., Davidson, K. W., Kessler, R. C., Asmundson, G. J. G., Goodwin, R. D., Kubzansky, L., Lydiard, R. B., Massie, M. J., Katon, W., Laden, S. K., et al. (2008) · Focus · doi:10.1176/foc.6.4.foc467 · Cited by 46
Novel treatment approaches for refractory anxiety disorders
Pollack, M. H., Otto, M. W., Roy-Byrne, P. P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · Depression and Anxiety · doi:10.1002/da.20329 · Cited by 77
Dopamine up-regulates Th17 phenotype from individuals with generalized anxiety disorder
Ferreira, T. B., Kasahara, T. M., Barros, P. O., Vieira, M. M. M., Bittencourt, V. C. B., Hygino, J., Andrade, R. M., Linhares, U. C., Andrade, A. F., & Bento, C. A. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.06.009 · Cited by 40
Decreased IFN-γ and IL-12 levels in panic disorder
Tükel, R., Arslan, B. A., Ertekin, B. A., Ertekin, E., Oflaz, S., Ergen, A., Kuruca, S. E., & İsbir, T. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.04.012 · Cited by 39
Amani, R., Fazelian, S., Paknahad, Z., Kheiri, S., & Khajehali, L. (2019) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_174_18 · Cited by 41
Ballesio, A., Zagaria, A., Vacca, M., Pariante, C. M., & Lombardo, C. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.05.006 · Cited by 32
Psychoimmunological effects of dioscorea in ovariectomized rats: role of anxiety level
Ho, Y., Wang, C.-F., Hsu, W., Tseng, T., Hsu, C., Kao, M.-D., & Tsai, Y. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-21 · Cited by 28
Basu‐Ray, I., Metri, K., Khanra, D., Revankar, R. R., Chinnaiyan, K. M., Raghuram, N., Mishra, M. C., Patwardhan, B., Sharma, M., Basavaraddi, I. V., et al. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03666-2 · Cited by 37
Stress-induced pro- and anti-inflammatory cytokine concentrations in panic disorder patients
Petrowski, K., Wichmann, S., & Kirschbaum, C. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.005 · Cited by 28
Elnazer, H. Y., Sampson, A. P., & Baldwin, D. S. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000356 · Cited by 21
Zhao, J., Ye, B., & Ma, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.715929 · Cited by 23
Barros, P. O., Ferreira, T. B., Vieira, M. M. M., Almeida, C. R. M., Araújo-Lima, C. F., Silva-Filho, R. G., Hygino, J., de Andrade, R. M., Andrade, A. F. B., & Bento, C. A. M. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9466-6 · Cited by 23
Lambert, R. A., Lorgelly, P. K., Harvey, I. M., & Poland, F. M. (2009) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-009-0114-5 · Cited by 20
Emotions and the Immune System
Kemeny, M. E. (2007) · Elsevier eBooks · doi:10.1016/b978-012088576-3/50035-6 · Cited by 20
Striatal microinjections of interleukin-2 and rat behaviour in the elevated plus-maze
Pawlak, C. R., & Schwarting, R. K. W. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.10.011 · Cited by 14
Time-dependent effects of striatal interleukin-2 on open field behaviour in rats
Karrenbauer, B. D., Ho, Y., Ludwig, V., Löhn, J., Spanagel, R., Schwarting, R. K. W., & Pawlak, C. R. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.12.003 · Cited by 14
Effect of anxiety on COVID ‐19 infection in hemodialysis patients
Kurtgöz, P. Ö., Saçkan, F., Kızılarslanoğlu, M. C., Bilgin, O., & Güney, İ. (2021) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13759 · Cited by 11
Koh, K. B., Sohn, S.-H., Kang, J. I., Lee, Y., & Lee, J. D. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2011.11.006 · Cited by 11
Self-citationNovel Treatment Approaches for Refractory Anxiety Disorders
Pollack, M. H., Otto, M. W., Roy‐Byrne, P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.4.foc486 · Cited by 9
Lambert, R., Caan, W., & McVicar, A. J. (2008) · Journal of Public Mental Health · doi:10.1108/17465729200800011 · Cited by 10
Potential Neuroimmunological Targets in the Treatment of Anxiety Disorders
Hou, R., Tang, Z., & Baldwin, D. S. (2013) · Modern Trends in Psychiatry · doi:10.1159/000351965 · Cited by 7
Gandarela, L., de A. Sampaio, T. P., Marçal, L., Burdmann, E. A., Neto, F. L., & Bernik, M. A. (2024) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2024.100779 · Cited by 6
“No significant differences in cell-mediated immunity were found in panic disorder patients after 6 weeks of CBT or CBT plus benzodiazepines (Koh and Lee, 2004).”
BackgroundResultKoh, K. B. (2018) · Springer eBooks · doi:10.1007/978-3-030-02783-4_4 · Cited by 5
Self-citationTreatment-Resistant Panic Disorder
Chen, M., & Tsai, S. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_13 · Cited by 5
Identity of Somatoform Disorders: Comparison with Depressive Disorders and Anxiety Disorders
Koh, K. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7119-6_1 · Cited by 3
Self-citationImmune response in Wistar rats with high and low level of situational anxiety
Лоскутова, Л. В., Idova, G. V., & Gevorgyan, M. M. (2007) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-007-0411-5 · Cited by 3
Antici, E. E., Kuhlman, K. R., Treanor, M., & Craske, M. G. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.03.002 · Cited by 4
Effects of experimentally induced panic attacks on neuroimmunological markers
de la Fontaine, L., Schwarz, M., Eser, D., Müller, N., Rupprecht, R., & Zwanzger, P. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0140-6 · Cited by 3
[Levels of adenosine deaminase and dipeptidyl peptidase IV in patients with panic disorder].
Yarpuz, A. Y., Yılmaz, A., Soykan, A., Elgün, S., & Kumbasar, H. (2008) · PubMed · Cited by 6
Biological Mechanisms of Somatization
Koh, K. B. (2018) · Springer eBooks · doi:10.1007/978-3-030-02783-4_9 · Cited by 3
Self-citationEmotion, Interventions, and Immunity
Koh, K. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7119-6_22 · Cited by 2
Self-citationDuygudurum ve Anksiyete Bozukluklarında Psikonöroimmünolojik Süreçler ve Psikoterapi ile İlişkisi
Yilmaz, C., & İkizer, G. (2022) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.943148 · Cited by 3
Basu‐Ray, I., & Metri, K. (2022) · Springer eBooks · doi:10.1007/978-981-16-6913-2_29 · Cited by 1
Psychoneuroimmunology and Chronic Pain
Giron, S. E. (2015) · Digital USD (University of San Diego) · doi:10.22371/07.2015.016
The Immune System and Anxiety Disorders
Michopoulos, V., & Jovanović, T. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108539623.013
Gandarela, L. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-08122021-140003
Metadata
- Authors
- Koh, K. B., & Lee, Y.
- Affiliations
- Yonsei University (KR)
- ORCID
- Lee, Youngjoon
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 73
- Issue
- 5
- Pages
- 286-292
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2020016982
- Cited by
- 53
- References
- 22
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 2 · 2013: 3 · 2012: 3
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.karger.com
- Licence
- cc-by-nc-nd
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Keywords
- panic disorder, anxiety, cell-mediated immunity, cognitive behavioral therapy, ethyl loflazepate, benzodiazepines, interleukin-2, lymphocyte proliferation, phytohemagglutinin, immune function, combined psychotherapy and pharmacotherapy
- MeSH terms
- Adult, Benzodiazepines, Female, Humans, Immunity, Cellular, Interleukin-2, Male, Middle Aged, Phytohemagglutinins, Psychiatric Status Rating Scales, Cognitive Behavioral Therapy, Panic Disorder, Treatment Outcome, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.